Neuren Pharmaceuticals Ltd has released a press release.
Appendix 4E and 2019 full year accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Update on trofinetide Phase 3 trial in Rett syndrome
- 2019 year-end update and 2020 outlook
- Patent to 2034 granted in Europe for Neurens NNZ-2591
- Phase 3 trial of trofinetide in Rett syndrome commences
- FDA Grants Orphan Drug Designation for Neuren's NNZ-2591 to Treat Angelman, Phelan-McDermid and Pitt Hopkins Syndromes
Later from Neuren Pharmaceuticals
- Rare Pediatric Disease designation received from FDA
- Commentary on potential benefit to Neuren of RPD designation
- Compelling results for 2591 dose ranging study in PMS model
- Neuren to capture substantially greater value after Phase 3
- Temporary pause in new enrolments for LAVENDER trial in US
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals